companiesCompany

Taiho Pharmaceutical (Otsuka)

Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.

Futibatinib approved 2022 (FOENIX-CCA2); Lonsurf (trifluridine/tipiracil) in colorectal and gastric cancer; TAS-102 combinations; Araris Biotech acquisition (2025) for ADC platform.

Headquarters

Tokyo, JP

Type

pharma

Website

www.taiho.co.jp/en/

Products

ApprovedSmall-molecule irreversible kinase inhibitor (FGFR1-4)

Futibatinib · Lytgobi

Futibatinib is a covalent FGFR inhibitor for FGFR2-fusion bile duct cancer, with the highest response rate of the first-generation drugs.

Connected

cancers

3

Biliary tract cancer (cholangiocarcinoma)Colorectal cancer Myelodysplastic syndromes / neoplasms (MDS)

fronts

2

Antibody-Drug Conjugates Targeted Therapy

drugs

1

ApprovedSmall-molecule irreversible kinase inhibitor (FGFR1-4)

Futibatinib · Lytgobi

companies

1

Araris Biotech (Taiho)